



**Contact:**

**QPS**

Ben Chien, PhD  
Chairman, President & CEO  
QPS Holdings, LLC  
Three Innovation Way, Suite 240  
Newark, DE 19711  
USA

+ 1 302-369-5110 DE office  
+ 1 650-599-9445 CA office  
ben.chien@qps-usa.com  
[www.qps-usa.com](http://www.qps-usa.com)

**Bioserve Clinical Research (P) Ltd**

Suneil S. Reddy  
Managing Director  
6-56/6/1A, Opp. IDPL, NH-9,  
Balanagar, Hyderabad  
AP 500 037  
India

Tel:+91 40 2377 0873, 2377 0874  
Fax:+91 40 2377 0877  
For business inquiries, [bd@bioserve.co.in](mailto:bd@bioserve.co.in)  
For general inquiries, [info@bioserve.co.in](mailto:info@bioserve.co.in)  
[suneil@bioserve.co.in](mailto:suneil@bioserve.co.in)  
[www.bioserve.co.in](http://www.bioserve.co.in)

**FOR IMMEDIATE RELEASE:**

## **QPS expands phase 1 and bioanalytical capability by acquisition of Bioserve, India.**

(January 25 , 2011; Newark, Delaware, USA and Hyderabad, India) QPS, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the acquisition of a majority stake in Bioserve Clinical Research. Bioserve, a full service phase 1 CRO headquartered in Hyderabad, India, will be known as QPS-Bioserve India.

QPS is a global CRO supporting drug discovery and development since 1995. Its five areas of expertise include: Preclinical DMPK/Tox, Bioanalytical, Translational Medicine, Early Stage Clinical and Late Stage Clinical Research.

Bioserve is an ISO 9001:2008 certified organization providing world-class clinical research services to sponsors across the globe. Its infrastructure includes a 92-bed clinical unit for conducting phase I studies and a bioanalytical lab equipped with multiple LC/MS/MS systems for small molecule bioanalysis. Over the past 6 years, it has conducted over 500 studies, with numerous product approvals, and has been inspected by the USFDA, UK MHRA, WHO and Indian DCGI.

“This new partnership further expands QPS’ global range of linearly integrated services,” said Ben Chien, PhD, Chairman, President and CEO of QPS. “With access to Bioserve's additional resources, our customers will have the heightened benefits of a third more phase I beds, bringing our total to 400; greater bioanalytical capacity; and access to another facility, located in India, with a reputation for outstanding performance and a

record of timely approvals. Furthermore, current customers will be reassured to learn that Mr. Suneil Reddy will remain as Managing Director.”

The company has been growing at a rate of over 50% per year, with a current team of over 100 employees. Clients include large Indian as well as Multinational pharmaceutical firms. Bioserve’s promoters - the founders of Vijaya Diagnostic Centre, one of the largest diagnostic health care companies in India - bring a wealth of 30 years experience in the healthcare and clinical domain, combined with a passion for quality.

###

### **About QPS**

*QPS provides GLP/GCP-compliant preclinical and clinical research services to pharmaceutical and biotechnology clients worldwide in the areas of Bioanalysis, Drug Metabolism and Pharmacokinetics, Translational Medicine, and Clinical Research. Founded by Dr. Ben Chien in 1995, QPS has Bioanalysis and Preclinical testing facilities at its Newark, DE headquarters; in Groningen, the Netherlands; and in Taipei, Taiwan. Early-phase clinical facilities are located in Springfield, MO; Taipei, Taiwan; and Groningen, the Netherlands. Business development offices are maintained in the US, Europe, and Asia.*

### **About Bioserve**

*Bioserve was established in 2004 as a regulatory class CRO, offering end-to-end services, primarily catering to the needs of the generic pharmaceutical industry. Bioserve focuses on sponsors’ requirements - quality, compliance, and time and cost effectiveness - while remaining reliable and responsive. Bioserve’s services include Phase I & Bioavailability/Bioequivalence studies, PK in Patient Populations, Bioanalytical Services, Statistical & IVIVC Analysis, Pharmacoscintigraphic Imaging, Clinical Trial Management and Regulatory Affairs.*